As a buy-side FA, KW Capital assisted a medical enterprise Yunzhao to acquire part of shares in a medical R&D project company

On March 4, 2022, Guangdong Yunzhao Medical Technology Co., Ltd.(“Yunzhao”), a key medical enterprise in Guangzhou, completed the SPA signing of buying shares of a medical R&D project company Guangzhou Yinliangqiang Biotechnology Co., Ltd. And this project company will focus on the clinical application and test of using Recombinant Human Interleukin-12 (“rhIL-12”) for Chronic Hepatitis B (“CHB”) medical treatment.

Thanks to the trust of Yunzhao to KW Capital, we have the honor to act as the sole buy-side financial advisor in this transaction. In the process, we designed an innovative transaction architecture, which effectively solved the concerns of both parties, so that the project can be successfully implemented.

Along the completion of this transaction, Yunzhao will become the controlling shareholder of this project. Aiming to make every effort to help CHB patients all around the world.